Lineage Cell Therapeutics, Inc.

LCTX · NYSE American

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.9%

Institutions48.2%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$14.56M	$9.50M	$13.37M	$1.12M	$1.83M	$3.52M	$4.99M	$1.40M	$972000	$1.36M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	$334000	$728000	$1.43M	$385000	$412000	$302000	$168000	$358000	$1.11M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	–	$13.97M	$2.92M	$1.44M	$3.10M	$4.69M	$3.29M	$5.57M	$5.93M
Gross profit as a percentage of revenue.	–	–	104.5%	260.3%	78.9%	88.3%	93.9%	235.8%	572.5%	436.9%
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$36.62M	-$21.48M	-$22.52M	-$49.21M	-$26.45M	-$38.88M	-$41.80M	-$38.90M	-$58.97M	-$65.81M
Operating income as a percentage of revenue.	-251.6%	-226.1%	-168.5%	-4393.8%	-1448.4%	-1106.0%	-837.9%	-2788.7%	-6066.6%	-4849.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$166000	$27000	-$80000	-$251000	-$36000	-$118000	-$794000	-$3.31M	$33.57M	-$47.41M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$-0.26	$-0.14	$0.00	$0.00	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	–	–	–	–	–	$0.00	$0.00	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$40.79M	$45.79M	$11.36M	$55.74M	$32.59M	$9.50M	$23.59M	$36.84M	$22.09M	$42.23M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$112.58M	$113.22M	$123.66M	$174.54M	$107.95M	$125.48M	$101.66M	$173.24M	$142.57M	$94.66M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	$70000	$152000	$932000	$95000
Everything the company owes — debt, unpaid bills, and other obligations.	$69.24M	$36.21M	$51.73M	$83.65M	$12.82M	$14.23M	$9.41M	$8.98M	$12.06M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$44.55M	$78.38M	$73.34M	$92.22M	$96.20M	$112.96M	$93.84M	$162.64M	$117.93M	$26.89M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$18.92M	-$23.09M	$1.06M	-$23.56M	-$19.75M	-$31.95M	-$30.88M	-$30.52M	-$42.33M	-$44.54M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$522000	$565000	$413000	$354000	$64000	$440000	$556000	$1.33M	$2.25M	$1.24M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$19.44M	-$23.66M	$646000	-$23.91M	-$19.82M	-$32.39M	-$31.44M	-$31.84M	-$44.57M	-$45.78M

	You	Peer avg
Revenue Growth	-61.3%	-17.6%
ROE	-60.1%	-300.0%

Lineage Cell Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison